AZD2014: Clinical Trials

14 trials of AZD2014, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 terminated, 2 unknown, 1 active not recruiting. 14 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Completed 7, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 25Terminated 2, Unknown 2, Recruiting 1

Follow AZD2014: new trials by email Literature Review of AZD2014 trials Research Report on AZD2014

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)152018-03-202023-10-17
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
acalabrutinib, vistusertib - DLBCL, Richter Syndrome
Phase 1 / Phase 2TerminatedAcerta Pharma BV252017-06-292021-01-06
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
AZD2014 - Glioblastoma Multiforme
Phase 1CompletedCanadian Cancer Trials Group152016-12-222023-08-04
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AZD2014, Ibrutinib - Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
Phase 1WithdrawnAstraZeneca2016-06-012016-09-15
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
AZD2014, Anastrozole - Endometrial Carcinoma, Metastatic Carcinoma
Phase 1 / Phase 2UnknownCentre Leon Berard722016-04-012024-02-13
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
AZD2014, Palbociclib, Fulvestrant - Advanced and Metastatic Breast Cancer
Phase 1CompletedAstraZeneca542015-12-072024-06-06
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer
Phase 1 / Phase 2UnknownQueen Mary University of London1182015-06-012020-02-25
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
AZD2014 - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca282015-03-172024-12-17
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Phase 1Active not recruitingM.D. Anderson Cancer Center1592014-11-112026-09-04
Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer
AZD2014 - Prostate Cancer
Phase 1CompletedCambridge University Hospitals NHS Foundation Trust232014-10-012019-07-17
A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
AZD2014 3 on/4 off & weekly paclitaxel, AZD2014 2 on/5 off & weekly paclitaxel - Advanced Cancer
Phase 1CompletedRoyal Marsden NHS Foundation Trust902013-04-262024-09-26
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
AZD2014, Fulvestrant - Advanced Metastatic Breast Cancer
Phase 1CompletedAstraZeneca992012-05-082026-02-24
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
AZD2014 - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca1722009-12-012016-02-11

Conditions studied

Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Carcinoma (1)  ·  Disease (1)  ·  Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Glioblastoma (1)  ·  Lymphoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Recurrence (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

AstraZeneca (5)  ·  Acerta Pharma BV (1)  ·  Cambridge University Hospitals NHS Foundation Trust (1)  ·  Canadian Cancer Trials Group (1)  ·  Centre Leon Berard (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Queen Mary University of London (1)  ·  Royal Marsden NHS Foundation Trust (1)

Countries

United Kingdom (7)  ·  United States (5)  ·  France (2)  ·  Canada (1)  ·  Denmark (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Spain (1)

Top investigators

Anja Wiliams (1)  ·  Birgit Geoerger, MD (1)  ·  Christine L Hann (1)  ·  Dr. Udai Banerji (1)  ·  Elisabeth Oelmann (1)  ·  Ian W Flinn, MD, PhD (1)  ·  Peter Schmid, Professor (1)  ·  Shannon N Westin (1)  ·  Simon C Pacey, MRCP, PhD (1)  ·  Udai Banerji, PhD (1)  ·  Warren Mason (1)

Results publications

PMID 30016392, PMID 31538815, PMID 31707687, PMID 32379297, PMID 33892407, PMID 34269152, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35551299, PMID 39998620, PMID 41838385, PMID 42686334

NIH funding

2014 (2), 2009 (1), 2015 (1), 2016 (1), P50CA083639 (1), UM1CA186691 (1)